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Abstract: We studied human bone healing characteristics and the histological osteogenic environment
by using devices made of a composite of uncalcined and unsintered hydroxyapatite (u-HA) and
poly-L-lactide (PLLA). In eight cases of fixation, we used u-HA/PLLA screws for maxillary alveolar
ridge augmentation, for which mandibular cortical bone block was used in preimplantation surgery.
Five appropriate samples with screws were evaluated histologically and immunohistochemically for
runt-related transcription factor 2 (RUNX2), transcription factor Sp7 (Osterix), and leptin receptor
(LepR). In all cases, histological evaluation revealed that bone components had completely surrounded
the u-HA/PLLA screws, and the bone was connected directly to the biomaterial. Inflammatory
cells did not invade the space between the bone and the u-HA/PLLA screw. Immunohistochemical
evaluation revealed that many cells were positive for RUNX2 or Osterix, which are markers for
osteoblast and osteoprogenitor cells, in the tissues surrounding u-HA/PLLA. In addition, many
bone marrow–derived mesenchymal stem cells were notably positive for both LepR and RUNX2.
The u-HA/PLLA material showed excellent bioactive osteoconductivity and a highly biocompatibility
with bone directly attached. In addition, our findings suggest that many bone marrow–derived
mesenchymal stem cells and mature osteoblast are present in the osteogenic environment created
with u-HA/PLLA screws and that this environment is suitable for osteogenesis.
Keywords: poly-L-lactide; uncalcined and unsintered hydroxyapatite; biocompatibility; osteoconductivity;
mesenchymal stem cell
1. Introduction
Titanium fixation devices have been used widely as a standard for maxillofacial surgery because
they are easy to operate and relatively inexpensive; however, plate removal may be necessary,
and various complications can be caused by the metal [1]. Therefore, bioresorbable fixation devices
made of synthetic polymers are currently used widely as an alternative material for internal fixation.
An ideal bioresorbable osteosynthesis device should have the proper modulus and high strength,
retain that strength as long as bone healing requires support, and be safely absorbed and disassembled
without a foreign body reaction that delays the bone-healing process.
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Bioabsorbable fixation devices made of high-strength uncalcined and unsintered hydroxyapatite
(u-HA) and poly-L-lactide (PLLA) composites have been developed to solve the mechanical and
biological problems of life-long implants [2]. Currently, Super FIXSORB MX® (Teijin Medical
Technologies Co., Ltd. Osaka, Japan), also known as OSTEOTRANS MX, can be used as a commercially
available u-HA/PLLA osteosynthesis bioresorbable device. This bioresorbable device, which consists
of u-HA and PLLA, is manufactured by a compression molding reinforcement process and a forging
process incorporating machining. Because of its composition and the special manufacturing process,
this device has higher mechanical strength and bioactivity [2–5]. The bioactivity of bioresorbable plates
is a major advantage, and their bone conduction and bone-binding ability [6,7], complete long-term
replacement of the human bone [8], and biocompatibility [6–8] have been reported. In addition,
we have previously reported the presence of osteoblast differentiation markers in the environment
surrounding u-HA/PLLA materials [7], which has already shown that u-HA/PLLA materials are
bioactive materials with excellent bone regeneration ability.
However, the bone-healing properties of this device and the histological environment for bone
healing remain unclear. In this study, we investigated bone-healing characteristics and the histological
environment for u-HA/PLLA composite devices to understand the in vivo environment when this
device is used in maxillofacial clinical treatment.
2. Materials and Methods
2.1. Preparation of Uncalcined and Unsintered Hydroxyapatite/Poly-L-lactide Composite Screws
In this study, we used the Super FIXSORB MX®screw (Teijin Medical Technologies Co., Ltd.
Osaka, Japan), comprising a forged composite of u-HA/PLLA (containing 30 weight fractions of raw
uncalcined, unsintered HA particles in composites). The screws have a diameter of 2.0 mm and a
length of 8–12 mm; u-HA particle size ranges from 0.2 to 20 µm (average size, 3–5 µm); the ratio of HA
weight to PLLA weight is 30/70; the ratio of calcium to phosphorus is 1.69 (moles); and CO32− level is
3.8 (percentage of moles). The composite material used in this study was the same as that reported in
the past [2].
2.2. Subjects
This study included eight consecutive patients (two men and six women; age range, 33–59 years)
who needed maxillary alveolar ridge augmentation as preimplantation surgery because their residual
bone width was <4 mm; informed consent to participate in the study was obtained from all the patients.
All operations were performed by a single oral and maxillofacial surgeon (Shintaro Sukegawa) from
April 2018 to March 2019 in the Department of Oral and Maxillofacial Surgery at Kagawa Prefectural
Central Hospital, Takamatsu, Kagawa, Japan. The cases of this study are shown in Table 1.
Table 1. Details of patients and u-HA/PLLA screws used.
Patient
Number
Sex
(Male/Female)
Age
(Years)
Screw Length
(mm)
Number
of Screws
Presence or Absence
of u-HA/PLLA Screws
in the Specimen
Period from the
Screw Placement to
Evaluation (Day)
1 Female 44 8.0 2 Presence 246
2 Female 57 8.0 2 Presence 209
3 Female 59 8.0 2 Absence 219
4 Female 55 12.0 3 Presence 203
5 Male 55 12.0 1 Absence 223
6 Female 33 12.0 1 Presence 209
7 Male 50 8.0 2 Presence 226
8 Female 58 8.0 2 Absence 212
u-HA/PLLA, uncalcined and unsintered hydroxyapatite/poly-L-lactide.
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2.3. Surgical Bone Augmentation Procedure
In the surgical operation, the amount of material necessary for bone augmentation was collected
from the buccal cortical bone block of the mandibular ramus. The cortical bone block was fixed to the
recipient site by using u-HA/PLLA screws. The screw fixing method consisted of the following steps:
(1) drilling to form a bone hole, (2) forming a tap with a screw tap, and (3) insertion of u-HA/PLLA
screws into the holes formed by self-tapping. The screw insertion torque was 5 N. The number of
screws used was selected to obtain stable fixation of the bone block (Figure 1a).
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it the use of computed tomography. (Figure 1b). At the time of implant placement, specimens were
coll cted with a 2.0 mm dia eter trephine bar (ACE Surgical Supply Company, Inc., Brockton, MA,
USA) (Figure 1c). All procedures were performed by the same exp rt surgeon (Shintaro Sukegawa) at
the same institution. This st dy was approved by the Ethics Committee of the Kagawa Prefectural
Central Hospital (Approval No. 879).
2.5. Preparation for Histological Evaluation
All samples were immediately fixed in 4% paraformaldehyde for 12 h and then decalcified in
10% ethylenediaminetetraacetic acid at 4 ◦C for 14 days. Samples were dehydrated with a graded
series, soaked in xylol several times, and embedded in paraffin. Thin serial sections were made
from samples embedded in paraffin. The sections were used for hematoxylin–eosin staining and
immunohistochemical study.
2.6. Immunohistochemistry
The expressions of runt-related transcription factor 2 (RUNX2), transcription factor Sp7 (Osterix),
and leptin receptor (LepR) were evaluated in an immunohistochemical study. The prepared sample
paraffin-embedded block was sectioned in thicknesses of 3 µm. These sections were deparaffinized
in xylene for 15 min and rehydrated in graded ethanol solution. To prevent endogenous peroxidase
activity, the sections were incubated in 0.3% H2O2 and methanol for 30 min. Antigen retrieval was
achieved by heat treatment with 10-mM citrate buffer solution at a pH of 9.0. After treatment with
normal serum, the sections were incubated with the primary antibodies for RUNX2 (Abcam plc.,
Cambridgesshire, ab23981, UK, dilution of 1:500), Osterix (Abcam plc., Cambridgesshire, ab22552, UK,
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dilution of 1:100), and LepR (Proteintech. 20966-1, USA, dilution of 1:50) at 4 ◦C overnight. To tag the
primary antibody, EnVision peroxidase detecting reagent (Dako, Carpinteria, CA, USA) was applied.
We identified the immunoreactive site by using the avidin–biotin complex method (Vector Laboratories,
Burlingame, CA, USA). Detection was performed with 3,3′-Diaminobenzidine (DAB), and the staining
results were observed with an optical microscope.
For double-fluorescent Immunohistochemistry (IHC), the abovementioned LepR and RUNX2
antibodies were used as primary antibodies. Antibodies were diluted with Can Get Signal (Toyobo,
Osaka, Japan). Anti-mouse IgG Alexa Fluor 488 (Life technologies, Waltham, MA, USA) and anti-rabbit
IgG Alexa Fluor 568 (Carlsbad, CA, USA) were used as secondary antibodies at a dilution of 1:200.
After the reactions, the specimens were stained with 1 mg/mL of DAPI (Dojindo Laboratories,
Kumamoto, Japan). The staining results were observed with a fluorescence microscope.
3. Results
3.1. Clinical Evaluation
Six months after anterior maxillary alveolar bone augmentation of preimplantation surgery, bone
width in all patients was sufficient for placing the dental implant. The transplanted cortical bone block
was fully engrafted in all patients. No complications were observed in any of the patients after dental
implant placement, and all results with the final prosthesis set were satisfactory. We used the trephine
bar to obtain eight specimens from the bone-constructed area with u-HA/PLLA screws at the time of
implant placement. Of these specimens, five in which the implant was placed in the same location as
the u-HA/PLLA screw were examined histologically.
3.2. Histopathological Evaluations
Eight specimens were examined for resected material by using hematoxylin–eosin staining. In five
specimens, we were able to observe both screws and the surrounding bone. In 2 cases (Cases 1 and 2), bone
components had completely surrounded the u-HA/PLLA screws (Figure 2a,c). The high magnification
field revealed that the bone was directly connected to the biomaterial and that inflammatory cells did
not invade the space between the bone and the u-HA/PLLA screw. There was no cellular infiltration
between the bone and the u-HA/PLLA screw, and the materials were completely continuous. No foreign
body reaction was induced around the u-HA/PLLA screws (Figure 2a,b,d,e). These findings indicate
that u-HA/PLLA screw has high bone compatibility.
In other cases (Cases 3–5) fibrous tissue was observed surrounding the u-HA/PLLA. This
histological character of the fibrous tissue was uniform, and there was no inflammation and bleeding.
Foreign body giant cells were not present in stromal tissue (Figure 3b,c,e,f,h,i). Furthermore, this
fibrous tissue contained bone tissue and was continuous (Figure 3c,f,i). These findings are different
from those reported in other two cases (Cases 1 and 2), but findings of both these cases suggested that
u-HA/PLLA screws are highly biocompatible. In addition, the results of all the three cases (Cases 3–5)
indicate the potential for bone making ability around the u-HA/PLLA.
3.3. Immunohistochemical Evaluations
To investigate the characteristics of fibrous tissue, we performed immunostaining. Because of
absence of inflammation and existing new bone, we selected the marker for preosteoblast (RUNX2,
Osterix) and mesenchymal stem cell marker (LepR). In the fibrous tissue, RUNX2- or Osterix-positive
cells were observed; these cells were spindle shape and scattered (Figure 4a,b). LepR-positive cells
were also observed in fibrous tissue and their shape was similar to RUNX2- or Osterix-positive cells
(Figure 4c). It was confirmed that a number of RUNX2-positive cells expressed LepR (Figure 4d–f).
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the surface of the composite material after immersion in a simulated body fluid in in vitro research [2].
When cells touch the surface of material, they usually attach, adhere, and spread. The first stage
of this interaction between cell and material depends on the characteristics of the material surface
to determine the behavior of the cell upon contact with the material. Osteoblasts have been found
to preferentially attach to HA particles via filopodia, demonstrating that HA provides a favorable
anchoring site for human osteoblast adhesion [15]. Hydroxyapatite on the surface of u-HA/PLLA
screw may play an important role in direct bonding with human bone. This osteoconductive feature is
a major advantage of this material.
Of histological importance is the lack of foreign body reaction around the u-HA/PLLA material.
In this study, new bone is formed through direct contact with material and human bone. For regenerative
bone formation, the implant material must elicit minimal inflammatory reaction. In the past, we
quantitatively evaluated the presence of CD68, considered a marker for macrophages, around
u-HA/PLLA screws. CD68 was rarely observed around the u-HA/PLLA material [7]. In this study,
inflammatory cells and giant cells against foreign bodies were not observed in any of the specimens
examined, indicating high biocompatibility of the u-HA/PLLA material.
There are two type of pathways in the bone-healing process: intramembranous ossification and
endochondral ossification [16]. Intramembrane ossification is a process formed by mesenchymal cells
that condense to become functional osteoblasts without cartilage formation. Endochondral ossification,
in contrast, is a process of replacing a cartilage template composed of chondrocytes differentiated from
mesenchymal stem cells with bone containing osteoblasts and osteoclasts. These cells are functionally
responsible for bone formation that directs the deposition and calcification of bone matrix. Osteoblasts
are induced through the expression of osteoblast-specific transcription factor RUNX2 and Osterix
from immature mesenchymal stromal cells [17,18]. In our immunostaining evaluation, RUNX2- or
Osterix-positive cells were localized in the tissue surrounding u-HA/PLLA material. These cells were
present in connective tissue and did not secrete bone matrix. Numerous preosteoblasts were present
in the surrounding stroma of u-HA/PLLA, which suggests that this microenvironment might form
bone tissue.
In recent studies, bone marrow derived mesenchymal stem cells have been identified as LepR-
positive cells in cell lineage analysis [19]. Yang et al. reported that approximately 60% of LepR-positive
cells expressed RUNX2 and that among the LepR-positive cells, the RUNX2-positive subpopulation
had higher stem cell capacity than did the RUNX2-negative subpopulation [19]. Furthermore, cells
that were both LepR and RUNX2 positive showed pluripotency in an in vitro culture system [20].
The findings by Yang et al. suggest that LepR- and RUNX2-positive cells are located upstream of
the differentiation tree of bone marrow mesenchymal cells. Our results also showed that LepR- and
RUNX2- double positive cells were expressed in the environment surrounding u-HA/PLLA screws.
It has already been shown that u-HA/PLLA materials are bioactive materials with excellent bone
regeneration ability. However, the bone formation environment has not been elucidated. This study
is the first report demonstrating the surrounding environment with LepR- and RUNX2-positive
cells following the placement of u-HA/PLLA screws. The results of this study suggested that the
bone formation environment performed with u-HA/PLLA screws may enable the expression of bone
marrow–derived mesenchymal cells, which is a good environment for bone formation. Moreover,
these findings indicate that the screw induce recruitment of bone marrow derived mesenchymal stem
cells (RUNX2/LeptinR double positive).
A limitation of this study was that it was not possible to evaluate the tissue changes over long
term for materials implanted in the human body. We evaluated the timing of dental implant placement
after bone formation and samples collected at the same time as the dental implant placement. Because
resorbable osteosynthesis cannot be removed without complications, investigation through animal
experiments may enable evaluation at other times. On the contrary, to the best of our knowledge,
the results of this study will help elucidate the bone-healing properties of, and the histological
Materials 2019, 12, 3681 8 of 9
environment created by, u-HA/PLLA bioresorbable material in human maxillofacial bone. This is
interesting and important with regard to the in vivo response to u-HA/PLLA bioresorbable materials.
5. Conclusions
The u-HA/PLLA screws demonstrated excellent bioactive osteoconductivity and high biocompatibility
with maxillofacial bone in this study. In the tissues surrounding the u-HA/PLLA material, many cells
were positive for RUNX2 and Osterix, the markers for osteoprogenitor cells. In addition, several bone
marrow–derived mesenchymal stem cells were positive for both LepR and RUNX2. These results
suggest that the bone formation stimulated by u-HA/PLLA screws may provide a good environment
for bone regenerative formation in maxillofacial surgery.
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